Fracture - Pipeline Review, H2 2014

Date: August 25, 2014
Pages: 73
Price:
US$ 2,000.00 US$ 1,500.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: F18F5EA6E73EN
Leaflet:

Download PDF Leaflet

Summary

Global Markets Direct’s, ‘Fracture - Pipeline Review, H2 2014’, provides an overview of the Fracture’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Fracture, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fracture and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Fracture
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Fracture and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Fracture products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Fracture pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Fracture
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Fracture pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Fracture Overview
Therapeutics Development
Pipeline Products for Fracture - Overview
Pipeline Products for Fracture - Comparative Analysis
Fracture - Therapeutics under Development by Companies
Fracture - Therapeutics under Investigation by Universities/Institutes
Fracture - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Fracture - Products under Development by Companies
Fracture - Products under Investigation by Universities/Institutes
Fracture - Companies Involved in Therapeutics Development
Eli Lilly and Company
Kuros Biosurgery AG
Novartis AG
Kolon Life Science, Inc.
TissueGene, Inc.
Radius Health, Inc.
Arcarios BV
Escape Therapeutics, Inc.
OrgaNext Research BV
Fracture - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
teriparatide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
abaloparatide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KUR-113 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bimagrumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(nandrolone decanoate + cholecalciferol) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rusalatide acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KLS-Bfr - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OsteoStem - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TG-B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stromal Cell Therapy For Fracture Repair - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bone Morphogenetic Protein Modulators - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Immunology, Metabolic and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs to Modulate PPAR-Delta for Immunology, Metabolic and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Immunology, Musculoskeletal and Metabolic Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fracture - Recent Pipeline Updates
Fracture - Dormant Projects
Fracture - Discontinued Products
Fracture - Product Development Milestones
Featured News & Press Releases
Mar 11, 2013: Merck Provides Update On Fosamax Product Liability Trial
Feb 11, 2013: UCB And Amgen Decide Not To Pursue Phase III Clinical Trial Program For CDP7851
Jan 07, 2013: Radius Provides Update On Pivotal Phase III Program For BA058-SC Injection
Oct 15, 2012: Daiichi Sankyo Announces Positive Phase III Study Results For Denosumab On Fracture Risk In Japanese Patients With Osteoporosis At ASBMR
Aug 07, 2012: Lilly Announces Study Results Regarding Postmenopausal Women With Back Pain Caused By Vertebral Fractures
Jan 24, 2011: Kuros Reports One Year Data From Phase IIb Study With KUR-111
Jun 02, 2010: Kuros Completes Patient Recruitment In A Phase IIB Trial Of KUR-113 In Patients With Tibial Shaft Fractures
Jun 01, 2010: Amgen Receives FDA Approval For Prolia For Treatment Of Postmenopausal Women With Osteoporosis At High Risk For Fracture
Mar 15, 2010: Kuros Meets Primary Efficacy Endpoint In Phase IIb Study With KUR-111
Jun 08, 2009: Kuros Completes Patient Recruitment In A Phase IIb Trial Of KUR-111 In Patients With Tibial Plateau Fractures
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Fracture, H2 2014
Number of Products under Development for Fracture - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Late Stage Development, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Development, H2 2014
Products under Development by Companies, H2 2014
Products under Investigation by Universities/Institutes, H2 2014
Fracture - Pipeline by Eli Lilly and Company, H2 2014
Fracture - Pipeline by Kuros Biosurgery AG, H2 2014
Fracture - Pipeline by Novartis AG, H2 2014
Fracture - Pipeline by Kolon Life Science, Inc., H2 2014
Fracture - Pipeline by TissueGene, Inc., H2 2014
Fracture - Pipeline by Radius Health, Inc., H2 2014
Fracture - Pipeline by Arcarios BV, H2 2014
Fracture - Pipeline by Escape Therapeutics, Inc., H2 2014
Fracture - Pipeline by OrgaNext Research BV, H2 2014
Assessment by Monotherapy Products, H2 2014
Assessment by Combination Products, H2 2014
Number of Products by Stage and Target, H2 2014
Number of Products by Stage and Mechanism of Action, H2 2014
Number of Products by Stage and Route of Administration, H2 2014
Number of Products by Stage and Molecule Type, H2 2014
Fracture Therapeutics - Recent Pipeline Updates, H2 2014
Fracture - Dormant Projects, H2 2014
Fracture - Discontinued Products, H2 2014

LIST OF FIGURES

Number of Products under Development for Fracture, H2 2014
Number of Products under Development for Fracture - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Comparative Analysis by Early Stage Products, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Top 10 Target, H2 2014
Number of Products by Stage and Top 10 Target, H2 2014
Number of Products by Top 10 Mechanism of Action, H2 2014
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014
Number of Products by Top 10 Route of Administration, H2 2014
Number of Products by Stage and Top 10 Route of Administration, H2 2014
Number of Products by Top 10 Molecule Type, H2 2014
Number of Products by Stage and Top 10 Molecule Type, H2 2014
Skip to top


Ask Your Question

Fracture - Pipeline Review, H2 2014
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: